

Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i) **Rossella Paolini**
 Incarico attuale Responsabile UOSD Ematologia Azienda 5 Polesana della Regione Veneto
 Telefono(i) 0425-394404
 Fax 0425-393280
 E-mail rossella.paolini@aulss5.veneto.it

Titoli di studio e professionali ed esperienze lavorative

Medico chirurgo
Specialista in Ematologia clinica e di laboratorio

Esperienza professionale

Maturata dal 1986 in Medicina interna e Ematologia presso l'Università di Padova (oncologica e coagulologica)

Date Dal 2006 Responsabile Struttura Semplice dipartimentale di Ematologia del Dipartimento di Medicina Interna dell'Ospedale di Rovigo

Istruzione e formazione

Maturità classica (Padova, 1978)

Date 2005 specialità in Immunologia clinica presso l'Università di Padova

Titolo della qualifica rilasciata 1993 specialità in Cardiologia presso la stessa Università

Principali tematiche/competenze professionali acquisite 1989 specialità in Ematologia presso la stessa Università

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione 1986 laurea in Medicina e Chirurgia presso la stessa Università

Livello nella classificazione nazionale o internazionale Lingua inglese B2; lingua francese elementare

Capacità e competenze personali

Gestione clinica del paziente internistico.
 Diagnosi e terapia delle malattie ematologiche: leucemie acute e croniche, malattie linfoproliferative croniche, mieloma multiplo e amiloidosi, sindromi mielodisplastiche, coagulopatie congenite e acquisite, piastrinopenie, malattie mieloproliferative croniche (leucemia mieloide cronica, policitemia vera, trombocitemia essenziale, mielofibrosi)

Capacità e competenze organizzative

Autonomia di gestione e ruolo di responsabilità di gestione e organizzazione di struttura semplice dipartimentale di ematologia

Capacità e competenze tecniche

Lettura di preparati citologici di striscio periferico e midollo osseo

Pubblicazioni

- 1) Paolini R, Zamboni S, Ramazzina E, Zampieri P, Cella G. Idiopathic thrombocytopenic purpura treated with steroid therapy does not prevent acute myocardial infarction. A case report. *Blood Coagulation and Fibrinolysis* 10:439-442; **1999**.
- 2) Paolini R, Poletti A, Ramazzina E, Menin C, Santacatterina M, Montagna M, Bonaldi L, Del Mistro A, Zamboni S, D'andrea E. Coexistence of cutaneous T-cell lymphoma and B-hairy cell leukemia. *American Journal of Hematology* 64: 197-202; **2000**.
- 3) Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). *American Journal of Hematology* 65(2): 177-178; **2000**.
- 4) Bertorelle R, Bonaldi L, Bianchini E, Ramazzina E, Del Mistro A, Zamboni S, Chieco-Bianchi L, Paolini R. The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild type. *Leukemia* 15(12): 2003-4; **2001**.
- 5) Armigliato M, Paolini R, Bianchini E, Monesi G, Zamboni S, D'Andrea E. Hashimoto's thyroiditis and Graves' disease associated with retroperitoneal fibrosis. *Thyroid* 12(9): 829-31; **2002**.
- 6) Paolini R, Bonaldi L, Bianchini E, Ramazzina E, Cella G. Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukaemia with trisomy 8, trisomy 21 and cutaneous involvement. *Eur J Haematol* 71(6): 466-9; **2003**.
- 7) Paolini R, Armigliato M, Zamboni S. Pulmonary hypertension and systemic diseases. *Current Drug Targets – Inflammation & Allergy* 3: 459-67; **2004**.
- 8) Armigliato M, Paolini R, Aggio S, Zamboni S, Galasso MP, Zonzin P, Cella G. Hyperthyroidism as a frequent cause of pulmonary hypertension: a prospective study. *Angiology* 57 (5): 600-606; **2006**.
- 9) Paolini R, Bianchini E, D'Andrea E, Ahl-Nahhas A, Banti E, Muzzio PC, Rubello D. FDG-PET detection of primary bone marrow large B-cell lymphoma in a patient with hairy cell leukemia. *Nucl Med Rev Cent East Eur* 2007;10(1):23-5.
- 10) Paolini R, Rampin L, Rodella E, Ramazzina E, Banti E, Ahl-Nahhas A, Rubello D. The prognostic value of FDG-PET/TAC in the management of Hodgkin's lymphoma: preliminary results of a prospective study. *Nuclear Medicine Review* 2007; 10(2): 87-90
- 11) Rodella E, Pacquola E, Bianchini E, Ramazzina E, Paolini R. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome. *Blood Coagulation & Fibrinolysis* 19(4):315-318; **2008**
- 12) Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. *Thromb Haemost.* 2009 Feb;101(2):233-8

13. Visco C et al ; Autoimmune haemolytic anemia in patients with CLL in association with IgVH status; **Haematologica** 2010
14. Ferreri AJM et al; clinical relevance of the dose of Cytarebine in the upfront treatment of primari CNS lymphomas with MTX-ARA-C combination; **The Oncologist** 2011
15. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P; EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. **Blood**. 2012 Jul 5;120(1):39-46
16. Visco C et al; Combination of rituximab, bendamustine and cytarabine for patients with non Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation; **JCO** 2013.
17. Visco C et al; Combination of rituximab, bendmustine and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukaemia; **Am J Hematology** 2013
18. Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. **Am J Hematol**. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546.
19. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, Scupoli MT, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C. **Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica**. 2014
20. Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlíkova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. **Haematologica**. 2015
21. Maffione AM, Paolini R, Rodella E, Ambrosio C, Rampin L, Lisato LC, Ballotta M, Pavanato G, Rubello D. Response criteria for malignant lymphoma. **Nucl Med Commun**. 2015 Apr;36(4):398-405
22. Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, **Paolini R**, Gurrieri C, Rigolin GM, Cuneo A, Martinelli G, Cavo M, Testoni N. GComplex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. **Genes Chromosomes Cancer**. 2016 Apr;55(4):375-88.
- 23) Central venous catheter-related right atrial thrombosis in a patient with Hodgkin's lymphoma. Lanza D, **Paolini R**, Rodella E, et al. **G Italiano di Cardiologia** (Rome) 2016 My; 17(5): 388-390

|

24. Epstein-Barr Virus-Positive Mucocutaneous Ulcer Mimicking Rectal Carcinoma at 18F-FDG PET/CT. Maffione AM, Rampin L, **Paolini R**, Rodella E, Lisato LC, Ballotta MR, Pavanato G, Montesi G, Colletti PM, Rubello D. **Clin Nucl Med.** 2017 Aug;42(8):645-646
25. Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. Gusella M, Bolzonella C, **Paolini R**, Rodella E, Bertolaso L, Scipioni C, Bellini S, Cuneo A, Pasini F, Ramazzina E. **Tumour Biol.** 2017 Feb;39(2)
26. Antiplatelet therapy in patients with glucose-6-phosphate dehydrogenases deficiency after percutaneous coronary intervention: A reappraisal for clinical and interventional cardiologists. Zuin M, Rigatelli G, Carraro M, Galasso MP, Dell'Avvocata F, **Paolini R**, Zuliani G, Roncon L. **Cardiovasc Revasc Med.** 2017 Apr - May;18(3):226-229.
27. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Alessandro Broccoli, Beatrice Casadei, Alice Morigi, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, Francesco Pisani, Michele Merli, Carlo Visco, **Rossella Paolini**, et al. **Oncotarget.** 2018 May 4; 9(34): 23443–23450
28. Lenalidomide in pretreated patients with diffuse large B cell lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, et al. **The Oncologist** 2019; 24(9):1246-1252.
29. Clinical characteristics and outcome of West Nile virus infection in patients with lymphoid neoplasms: an Italian multicentre study. Visentin A, Nasillo V, Marchetti M, Ferrarini I, **Paolini R**, et al. **Hemasphere** 2020.
30. Hematol Oncol. 2021 Mar 19.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group [Rigolin](#) GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G., Zampogna G, Cibien F, Vitagliano N, Coscia M, Farina L, Gaidano G, Varettoni M, Paolini R et al
31. Splenomegaly as the first manifestation of thyroid cancer metastases. Paolini R, Toffoli S, Poletti A, Casara D, Moschino P, Fabris F, Girolami A. **Tumori.** 1997 Jul-Aug;83(4):779-82.
32. The Release of Tissue Factor Pathway Inhibitor and Platelet Factor 4 After Heparin Injection in Patients with Thrombocytosis. Cella G, Conard J, Manai S, Luzzatto G, Paolini R, Toffoli S, Boeri G, Vianello A, Girolami A, Samama MM, Strauss WE. **Hematology.** 1997;2(3):235-41
33. Normalization of the prolactin values during alfa-interferon therapy: the considerations with a female patient with anti-HCV-positive chronic hepatitis and prolactin-secreting hypophyseal microadenoma]. Zennaro R, Petracca EG, Paolini R, Ramazzina E. **Clin Ter.** 1996 Apr;147(4):169-71
34. B non-Hodgkin's lymphoma in a haemophilia patient with idiopathic CD4+ T-lymphocytopenia. Paolini R, D'Andrea E, Poletti A, Del Mistro A, Zerbinati P, Girolami A. **Leuk Lymphoma.** 1996
35. Remission of leukaemic meningitis after fludarabine. **Paolini R**, Ramazzina E, Zennaro R, Rimondi AP, Petracca GE, Zamboni S. **Lancet.** 1995 Oct 7;346(8980):972.

36. Tissue factor pathway inhibitor activity in factor VII deficiency. Cella G, Vianello A, Boeri G, Toffoli S, Paolini R, Rampin E, Girolami A. **J Med.** **1995**;26(3-4):189-91.
37. Anti-hepatitis C virus serology in patients affected with congenital coagulation defects: a comparative study using three second generation ELISA tests. Paolini R, Marson P, Vicarioto M, Ongaro G, Viero M, Girolami A. **Transfus Sci.** **1994**
38. Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation. Paolini R, Casonato A, Boeri G, Luzzatto G, Girolami A, Sasahara AA, Cella G. **J Med.** **1993**
39. Mild haemophilia A fails to protect from coronary artery disease: the report of two cases. Paolini R, Viero M, Pietrogrande F, Girolami A. **Haematologia (Budap).** **1993**;25(3):179-84
40. Interaction between histidine-rich glycoprotein and platelet factor 4 with dermatan sulfate and low-molecular-weight dermatan sulfate.
Cella G, Boeri G, Saggiorato G, **Paolini R**, Luzzatto G, Terribile VI. **Angiology.** **1992**
41. Heparin released platelet factor 4 in uncomplicated type 1 diabetes mellitus. Cella G, **Paolini R**. **Thromb Res.** **1991** Jun 1;62(5):603-4.
- 42 Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin. Luzzatto G, **Paolini R**, Stevanato F, Simioni P, Cella G. **Angiology.** **1989** Mar;40(3):170-4
- 43.Heparin-induced platelet factor 4 release by serial heparin injections. Stevanato F, **Paolini R**, Sgarbossa G, Simioni P, Cella G. **J Nucl Med Allied Sci.** **1988**
- 44.Changes in plasma levels of myoglobin, CPK and CPK-MB in patients subjected to percutaneous coronary angioplasty]. Pauletto P, Piccolo D, Scannapieco G, **Paolini R**, Caroli M, Corbara F, Cuman G, Chioin R, Casiglia E, Maddalena F, et al. **Cardiologia.** **1987 Oct**;32(10):1125-9.
- 45.[Rituximab and Bendamustine \(BR\) Compared with Rituximab, Bendamustine, and Cytarabine \(R-BAC\) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.](#) Bega G, Olivieri J, Riva M, Scapinello G, **Paolini R**, Finotto S, Sartori R, Lucchini E, Guandalini G, Facchinelli D, Tisi MC, Basso M, Ballotta L, Piazza F, Ferrarini I, Visco C. **Cancers (Basel).** **2021 Dec 3**;13(23):6089.

Il presente curriculum è redatto ai sensi e nel rispetto degli artt. 19, 46 e 47 del D.P.R. 445/2000 e nella consapevolezza delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 del D.P.R. 445 del 28 dicembre 2000.

Autorizzo il trattamento dei dati personali contenuti nel presente C.V., ai sensi del Regolamento UE 2016/679 e del Codice della Privacy (Decreto Legislativo n. 196/2003 e ss.mm.ii.)

FIRMA

Rossella Paolini

Rovigo, 26.3.2023